Crinetics Pharmaceuticals secured FDA approval for Palsonify (paltusotine), the first oral, once-daily first-line therapy for adults with acromegaly. This rare endocrine disorder results from excessive growth hormone production by the pituitary gland. The pill will compete against existing injectable blockbuster treatments from Novartis and Ipsen. The approval follows late-stage trials demonstrating significant hormone lowering with an acceptable safety profile. The drug targets patients ineligible for surgery or with inadequate surgical response, marking a pivotal advancement in oral treatment options for acromegaly.